top of page
$21.40
chg
-0.23 (-1.06%)
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
18.2
52 wk hi
32.44
Cash
$505.6 M
Burn Rate (Qtr)
$21.0 M
Mkt Cap
$597.7m
Avg Volume
224,403
*cash/burn updated:
Q1 '22
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
ANAB
Company Profile
AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.
Recent Posts
See what the community is saying - click to see full post.
bottom of page